Hepatic Outcomes of Nonalcoholic Fatty Liver Disease Including Cirrhosis and Hepatocellular Carcinoma

Alqahtani SA 1 , Chan WK 2 , Yu ML 3

Affiliations 

  • 1 Division of Gastroenterology and Hepatology, Johns Hopkins University, Baltimore, MD, USA; Liver Transplant Center, King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia. Electronic address: salqaht1@jhmi.edu
  • 2 Gastroenterology and Hepatology Unit, Department of Medicine, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia
  • 3 School of Medicine, College of Medicine, National Sun Yat-Sen University, Kaohsiung, Taiwan; Hepatitis Research Center, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan; Hepatobiliary Section, Department of Internal Medicine, Hepatitis Center, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan; Division of Hepato-Gastroenterology, Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital, Kaohsiung, Taiwan
Clin Liver Dis, 2023 May;27(2):211-223.
PMID: 37024203 DOI: 10.1016/j.cld.2023.01.019

Abstract

Nonalcoholic fatty liver disease (NAFLD) is the most common chronic liver disease worldwide and represents a significant cause of cirrhosis and hepatocellular carcinoma (HCC). Almost 20% of patients with NAFLD and advanced fibrosis develop cirrhosis, of which 20% can progress to decompensated liver stage. Although patients with cirrhosis or fibrosis continue to have a high risk for HCC progression, growing evidence shows that NAFLD-HCC can develop even in the absence of cirrhosis. Current evidence characterizes NAFLD-HCC primarily as a condition with late presentation, lower response to curative therapy, and poor prognosis.

* Title and MeSH Headings from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

MeSH terms
Similar publications